Abdulqadir J. Nashwan
Hamad Medical Corporation
450 Papers
139 Citations
Abdulqadir J. Nashwan is an academic researcher from Hamad Medical Corporation. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 11, co-authored 86 publications. Previous affiliations of Abdulqadir J. Nashwan include University of Calgary & Qatar Airways.
Chat about Author
Papers
Personalized nutrition, microbiota, and metabolism: A triad for eudaimonia
Muhammad Sarfraz,Aqsa Shahid,Samra Asghar,Bilal Aslam,Usman Ali Ashfaq,Hammad Raza,Miguel A. Prieto,Jesus Simal-Gandara,Francisco J. Barba,Muhammad Shahid Riaz Rajoka,Mohsin Khurshid,Abdulqadir J. Nashwan +11 more
TL;DR: In this paper , the authors have described recent developments in understanding the disparities of gut microbiota populations between individuals and the primary role of diet-microbiota interactions in modulating human physiology.
Effects of ABO blood groups and RH-factor on COVID-19 transmission, course and outcome: A review
Mohammad T. Abuawwad,Mohammad J. J. Taha,Luai Abu-Ismail,Warda A. Alrubasy,Shams Khalid Sameer,Ibrahim T. Abuawwad,Yaqeen Al-Bustanji,Abdulqadir J. Nashwan +7 more
TL;DR: In this paper , a link has been drawn between blood groups and COVID-19 transmission, course and prognosis, as literature suggests that blood group O plays a protective role against the infection, while blood group A exhibits a higher risk of exacerbation.
Assessing Bone Marrow Activity with [18F]FLT PET in Patients with Essential Thrombocythemia and Prefibrotic Myelofibrosis: A Proof of Concept
Mohamed A. Yassin,Sadek Nehmeh,Abdulqadir J. Nashwan,Samah Kohla,Shehab F Mohamed,Omer Ismail,Ahmad Al-Sabbagh,Dina Sameh Soliman,Lajos Szabados,Hadi Fayad +9 more
TL;DR: TLG of the LSpine in FLT PET images is a potential quantitative parameter to distinguish between ET and pre-PMF patients, and compared to gold standard bone marrow results, TLG can separate ET and Pre- PMF patients.
6
Clinical outcomes of post-renal transplant patients with COVID-19 infection in the ICU: A single-center case series
Nissar Shaikh,Mohamad Y. Khatib,Mohammad A. Alwraidat,Dore C. Ananthegowda,Muftah Othman,Asra Aroos,Sagar B. Jujjavarapu,Saptarshi Banerjee,Zishan Nasir,Ahmed S. Mohamed,Moustafa S. Elshafei,Muna Almaslamani,Abdulqadir J. Nashwan +12 more
TL;DR: Most of the post-renal transplant patients are taking immunosuppressive medications, including calcineurin inhibitors, anti-proliferative agents, and steroids.
5